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Abstract: Inflammatory biomarkers play a pivotal role in atherosclerotic lesions. The plasma levels of these markers are 
predictive of adverse outcomes such as myocardial infarction and cardiovascular death. The immune system is involved at 
all stages of atherogenesis via activation of monocytes/macrophages and T lymphocytes. Circulating proinflammatory  
cytokines and chemokines produced by these cells interact with specific receptors on various cells and activate specific 
signaling pathways, leading to inflammation-induced atherosclerotic lesions. Recent studies have focused on predictive 
value of inflammatory biomarkers such as C-reactive protein and interleukin-6. These biomarkers were shown to be  
associated  with  poor  quality  of life  and  predictive  of  adverse  events  in  coronary  atherosclerosis  and  left  ventricular  
dysfunction. Vascular predictive value of other numerous inflammatory markers is being investigated. We herein analyze 
the role of several mediators of inflammation, affecting vascular functions and leading toward atherosclerotic lesions. 
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INTRODUCTION 
  Inflammatory biomarkers play a pivotal role in the initia-
tion  and  propagation  of  atherosclerosis. I nflammation  ac-
companies coronary artery spasm, impaired coronary blood 
flow, myocardial  ischemia and restenosis  after angioplasty 
[1-3]. Surprisingly, the first inflammatory characteristics of 
atherosclerotic lesions were presented by European surgeons 
almost two centuries ago [4]. However, atherosclerosis was 
categorized  to  inflammatory  diseases  by  Russell  Ross  in 
1999 [5]. 
  Vascular  endothelial  dysfunction  and  lipoprotein  reten-
tion in the arterial intima are the earliest events in athero-
genesis that promote the release of cytokines and chemoki-
nes, both of which are responsible for leukocyte recruitment. 
These events followed by activation of T lymphocytes, par-
ticularly T helpers, which facilitate cascade of events related 
to oxidized low density lipoproteins (LDL) [6, 7]. Circulat-
ing  pro-inflammatory  cytokines  produced  by  monocytes/ 
macrophages  and  T  lymphocytes  interact  with  platelet  
derived inflammatory and prothrombotic agents and activate 
specific signaling pathways, initiating cells adhesion, apop-
tosis and increased permeability of the endothelium. These 
cytokines are also responsible for oxidative stress [8]. 
  Recent  studies  have  demonstrated  vascular  predictive 
value of several inflammatory markers [9-11] and associa-
tion  of  these  markers  with  established  cardiovascular  risk 
factors, such as dyslipidemia, cigarette smoking, hypertension, 
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diabetes, obesity [12-16]. Oxidation of LDL and modifica-
tion of other lipoproteins induce overexpression of inflam-
matory  cytokines  and  other
  mediators  of  inflammation  in 
vessels  [17-20].  Studies  on  the  link  between  hypertension 
and inflammation have  also shown that angiotensin II can 
lead toward hypertension through activation of inflammatory 
cascades and atherogenesis [21]. It is also known that hyper-
glycemic profiles in diabetes are associated with overproduc-
tion of pro-inflammatory cytokines by vascular endothelial 
cells [22]. In obese subjects, the adipose tissue can synthe-
size  cytokines  (e.g.,  tumor  necrosis  factor  alpha  [TNF-α]  
and  interleukin-6  [IL-6])  and,  thus,  promote  inflammatory 
atherogenesis [23]. 
  Recent studies have also shown that suppression of di-
verse  inflammatory  mediators  may  retard  atherosclerotic 
process.  Interestingly,  evidence  indicates  that  knockout  of 
interferon-γ (IFN-γ) [24] and interleukin-18 (IL-18) [25, 26] 
is crucial for retardation of atherosclerosis. Established car-
diovascular  risk  factors  modification  can  reduce  levels  of 
circulating  inflammatory  markers  and  improve  endothelial 
function [27]. The atherogenic role of inflammation has also 
been confirmed within the frames of chronic low- and high-
grade inflammatory disorders such as diabetes, periodontal 
disease,  familial  Mediterranean  fever,  lupus,  antiphosphol-
ipid syndrome, rheumatoid arthritis, systemic sclerosis, end-
stage renal disease [28-32].  
  We herein analyze  the role of several  mediators of in-
flammation, affecting vascular functions and leading toward 
atherosclerotic lesions. 
C-REACTIVE PROTEIN (CRP) 
  Acute-phase  reactants  are  produced  in  response  to 
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are  two  important  sources  of  CRP  implicated  in  athero- 
thrombosis:  local  production  in  atherosclerotic  plaques  
and in adipose tissue [33]. CRP is able to stimulate produc-
tion  of  plaque-destabilizing  matrix  metalloproteinases 
(MMPs) and monocyte chemoattractant protein 1 (MCP-1). 
It  also  can  decrease  activity  of  endothelial  nitric  oxide  
synthase  (eNOS)  and  impair  endothelium-dependent  
vasodilation [34].  
  High sensitivity CRP (hs-CRP) levels have been proved 
to be strongly predictive of cardiovascular events and poten-
tially associated with the severity of coronary atherosclerosis 
[35-39].  Utility  of  this  biomarker  for  cardiovascular  risk 
stratification  in  populations  with  and  without  established 
cardiovascular  disease  is  supported  by  strong  evidence  
[40]. In particular, it was shown that survival rate following 
percutaneous coronary intervention in patients with angina 
was significantly  low  in those with high CRP  levels [41]. 
Not less importantly, very high levels of CRP were associ-
ated with poor quality of life, high incidence of depressive 
symptoms  and  physical  inactivity  [42].  Associations  were 
also  found  between  hs-CRP  and  ischemic  heart  disease,  
left  ventricular  ejection  fraction,  congestive  heart  failure  
[43, 44]. 
  Four  CRP  polymorphisms  were  associated  with  64% 
increase in CRP levels, resulting in predicted increased risk 
of  ischemic  heart  disease  and  ischemic  cerebrovascular  
disease by 32% and 25%, respectively [45].  
FIBRINOGEN 
  Fibrinogen contributes to atherosclerosis through several 
mechanisms: 1. propagation of atherosclerosis via adhesion 
of  white  blood  cells  to  the  endothelium,  stimulation  of 
smooth  muscle  cells  (SMCs)  proliferation  and  release  of 
endothelium-derived growth factor; 2. aggregation of plate-
lets; 3. increase of plasma viscosity [46, 47]. Fibrinogen may 
play an active role in the development
 and destabilization of 
atherosclerotic plaques. Several prospective trials have dem-
onstrated strong vascular predictive value of this biomarker 
[48-52]. In one study, adjusted hazard ratio for atherosclero-
sis progression for the highest quartile of baseline fibrinogen 
was 2.45 [53]. It was also suggested that this hazard ratio can 
be especially high in younger patients [54]. Population stud-
ies allowed to suggest that high prevalence of cardiovascular 
disease  can  be  genetically  determined  and  linked  to  locus  
in  the  7
th  pair  of  chromosome  encoding  fibrinogen  [55]. 
Findings have also indicated that high fibrinogen levels and 
genetic variation in fibrinogen-α and fibrinogen-γ genes may 
be associated with arterial stiffness [56].  
SERUM AMYLOID A (SAA) 
  SAA belongs  to the family of apolipoproteins. SAA is 
produced by liver and reticuloendothelial tissue in response 
to inflammatory stimuli, and circulates in complex with high 
density lipoprotein (HDL). It has been suggested that SAA 
can  stimulate  pro-inflammatory  cytokines  production  by 
monocytes/macrophage  and  thereby  contribute  to  the  pro-
inflammatory state in coronary artery disease [57]. Further-
more,  the role of SAA in the prediction of cardiovascular 
events has been proved [58].  
TUMOR NECROSIS FACTOR ALPHA (TNF-α) 
  TNF-α is a secretory product of macrophages that acti-
vates endothelial cells, stimulates angiogenesis, and induces 
proliferation  of  SMCs.  The  expression  of  TNF-α  in  both 
intimal  and  medial  SMCs  and  macrophages  is  associated 
with the progression of atherosclerosis [59]. Significant cor-
relation was found between TNF-α and severity of coronary 
artery disease assessed by the number of obstructed coronary 
vessels and the Gensini severity score [60]. 
  TNF-α is actively involved in the progression of athero-
sclerosis [61-63]. It was demonstrated that elevated soluble 
TNF receptor 1 (sTNF-R1) can predict cardiovascular mor-
tality in patients with chronic heart failure [64]. Activity of 
TNF and its receptor may also has additive role in athero-
sclerosis induced by homocysteine in patients with diabetes 
[65]. 
MONOCYTE  CHEMOATTRACTANT  PROTEIN-1 
(MCP-1) 
  MCP-1 is a member of the CC chemokine superfamily 
that  activates  monocytes  at  acute  stage  of  inflammation. 
MCP-1  induces  migration  of  monocytes/macrophages,  as 
well  as  CD4+  and  CD8+  T  lymphocytes  into  the  sub-
endothelial space [66-69]. MCP-1 expression can be induced 
by IL-1b and TNF-alpha through the activation of nuclear 
factor-kB  [70,  71].  MCP-1  facilitates  oxidation  of  choles-
terol and through it contributes to the development of fatty 
streaks  in  hypercholesterolemia  [72].  Interestingly,  MCP-1 
inhibition  in  apolipoprotein-E  knockout  mice  prevents 
atherogenesis [73]. 
INTERLEUKIN-6 (IL-6) 
  IL-6 is a well-known risk marker of cardiovascular dis-
ease associated with obesity, type 2 diabetes and myocardial 
infarction. The relationship between IL-6, the Gensini sever-
ity  score  and >70% stenosis of  coronary vessels has been  
already proved [74, 75]. IL-6 levels are also independently 
associated with subclinical atherosclerotic  lesions [76, 77], 
and proved to be predictive of ischemic events [78]. 
  IL-6  induces  secretion  of  other  inflammatory  markers, 
particularly CRP. IL-6 activates cell-surface signaling via the 
assembly of IL-6, its receptor (IL-6R) and signaling receptor 
gp130 [79]. Haddya et al., demonstrated positive correlation 
between  IL-6,  TNF-α  and  CRP  in  parents  and  their  
offsprings.  Furthermore,  they  found  negative  relationship 
between IL-6 and HDL-cholesterol [80]. 
INTERLEUKIN-8 (IL-8) 
  IL-8  is  another  cytokine,  mediator  of  angiogenesis  in 
coronary atherosclerosis,  inducing  migration and prolifera-
tion of endothelial cells and smooth muscle cells [81]. Re-
cently,  macrophages  from  atherosclerotic  plaques  were 
found to express the IL-8 receptor (CXCR2). This expres-
sion is pro-atherogenic. CXCR2 deficiency retards progres-
sion of atherosclerosis in animal models [82]. Besides, ele-
vated levels of IL-8 are associated with an increased risk of 
coronary artery disease [83]. 
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INTERLEUKIN-1 (IL-1) 
  IL-1  is  a  pro-inflammatory  cytokine  that  increases  
production  of  other  cytokines  and  induces  expression  of  
adhesion  molecules  on  endothelial  cells.  In  addition,  IL-1 
contributes to the tissue damage by stimulating cell prolifera-
tion  and release of  matrix  metalloproteinases. Overexpres-
sion of IL-1 receptor antagonist (IL-1Ra) inhibits the devel-
opment  of  atherosclerotic  lesions.  Moreover,  inhibition  of 
IL-1β  decreases  severity  of  atherosclerosis  through  the  
increased expression of VCAM-1 and MCP-1 [84, 85].  
INTERLEUKIN-4 (IL-4) 
  Deficiency  of  IL-4  can  reduce  atherosclerotic  lesions 
[86].  This  cytokine  increases  the  number  of  cell-surface 
binding sites for LDL. IL-4 can have profound effect on the 
macrophage lipid metabolism within atherosclerotic lesions 
[87].  
INTERLEUKIN-10 (IL-10) 
  The role of IL-10 in the inflammatory process is dual, 
pro-  and  anti-inflammatory  [88].  Cumulative  incidence  of 
coronary artery disease was significantly greater in individu-
als with IL-10 concentrations ≥1.04 pg/Ml and one standard 
deviation increase in baseline IL-10 concentration was asso-
ciated with a 34% greater risk of this event [89]. This inter-
leukin is expressed in human atherosclerotic plaques, and it 
can  modulate  local  inflammatory  response  by  preventing 
excessive cell death in the plaque [90]. In a study on animal 
models,  increased  T-cell  infiltration,  abundant  interferon-
gamma  expression  and  decreased  collagen  content  were 
shown in the atherosclerotic lesions of IL-10-deficient mice. 
IL-10 appeared to be crucial for protection against the effect 
of environmental pathogens on atherosclerosis [91]. 
INTERLEUKIN-12 (IL-12) 
  Recent  data  suggest  that  IL-12  plays  an  active  role  in 
regulating  immune  response  during  initial  atherosclerotic 
changes in animal models. Daily administration of IL-12 was 
shown  to  increase  serum  levels  of  antibodies  against  
oxidized  LDL  [92].  IL-12  can  also  induce  T  lymphocytes 
recruitment into atherosclerotic plaque [93].  
INTERLEUKIN-15 (IL-15) 
  Plasma levels of IL-15 were found to be high in patients 
with  coronary  artery  disease,  compared  to  those  without 
coronary artery disease [94]. This cytokine is up-regulated in 
atherosclerotic lesions, where it stimulates recruitment of T 
lymphocytes [95]. The expression of IL-15 is found almost 
exclusively in fibrolipid and lipid-rich plaques in  complex 
foam cells [96]. 
INTERLEUKIN-18 (IL-18) 
  IL-18 is a pro-inflammatory cytokine secreted by mono-
nuclear cells. The serum concentrations of this cytokine have 
been shown to be predictive of mortality in coronary artery 
disease [97]. Patients in the highest quartile for this marker 
had greater risk of cardiovascular death, compared to those 
in the lowest quartile [98]. Recent findings have indicated a 
role  of  IL-18  in  progression  of  atherosclerosis  at  its  early  
and  late  stages  [99].  It  has  also  been  shown  that,  despite  
increased  activity  of  T  lymphocytes  and  increased  serum 
levels of cholesterol, there is no progression of atherosclero-
sis  in  the  absence  of  IL-18  [100].  Pro-atherogenic  effect  
of  IL-18  is  strongly  dependent  on  IFN-γ  produced  by  T  
lymphocytes, macrophages, natural killer cells and vascular 
cells [101]. 
INTERLEUKIN-33 (IL-33) 
  IL-33 is a member of the IL-1 family that induces differ-
entiation of T lymphocytes and is involved in T-cell medi-
ated immune responses. IL-33 regulates production of IL-5, 
IL-4, IL-13 and can decrease levels of IFN-γ in the serum 
and lymph nodes [102]. It is also involved in the production 
of antibodies against oxidized LDL [103]. 
INTERCELLULAR  ADHESION  MOLECULE-1 
(ICAM-1) 
  ICAM-1  is  a  member  of  the  immunoglobulin  superfa-
mily.  Its  role  relates  to  leukocytes  migration  into  tissues. 
ICAM-1 can contribute to inflammatory responses within the 
blood  vessel  wall  by  increasing  endothelial  cell  activation 
and augmenting atherosclerotic plaque formation. Its expres-
sion  is  up-regulated  in  atherosclerotic  plaques  in  human 
coronary  arteries  [104,  105].  Besides,  it  was  shown  that 
soluble ICAM-1 is correlated with the severity of atheroscle-
rosis, that its inhibition can retard atherogenesis [106-108] 
and that ICAM-1 can serve as a predictor of vascular events 
[109].  
VASCULAR  CELL  ADHESION  MOLECULE-1 
(VCAM-1) 
  VCAM-1 facilitates adhesion of most inflammatory cells 
(monocytes,  lymphocytes,  eosinophils  etc.) to  the vascular 
wall  and  monocytes  recruitment  into  atherosclerotic  sites 
[110].  
METALLOPROTEINASES (MMPS) 
  Monocyte/macrophage-derived  MMPs  are  zinc-
dependent endoproteases with collagenase and/or
 gelatinase 
activity  [111].  These  agents  damage  the  endothelium  and 
collagen fibrils in atherosclerotic plaques, thus accelerating 
the process of atherothrombosis [112-116]. 
CONCLUDING REMARKS 
  Clinical implications of inflammation in atherosclerosis 
have been acknowledged in the past decade. Diverse markers 
of inflammation have been associated with adverse vascular 
events and inefficiency of primary and secondary cardiovas-
cular prevention [117]. The concept that inflammation con-
tributes to atherosclerotic cardiovascular disease has had a 
remarkable impact on our understanding of atherothrombosis 
that is no longer considered as a reflection of lipid disorders, 
but rather as a disorder characterized by low-grade vascular 
inflammation. 
  Population-based studies have proved that elevated levels 
of several inflammatory mediators have predictive values for 
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tive studies have demonstrated increased vascular risk asso-
ciated  with  increased  baseline  levels  of  pro-inflammatory 
cytokines (IL-6 and TNF-α) [118], cell adhesion molecules 
(ICAM-1, P-selectin, E-selectin [119] and acute-phase reac-
tants (CRP, fibrinogen, serum amyloid A) [120]. It has re-
cently been suggested that hs-CRP is a well validated bio-
marker with predictive value. Benefits of hs-CRP for strati-
fying the risk of atherosclerotic events have been confirmed. 
It is the most useful predictive marker of recurrent adverse 
events, including death, myocardial infarction and restenosis 
after cardiac revascularization [121]. 
  In contrast  to cytokines,  CRP has  a long half-life with 
stability  of  levels  with  no  observable  circadian  variation 
[122]. In addition, there are well validated assays for detec-
tion of CRP in freshly frozen and stored plasma [123]. The 
American  Heart  Association  and  the  Centers  for  Disease 
Control  and  Prevention  have  published  a  joint  scientific 
statement on the use of inflammatory markers, particularly 
hs-CRP in clinical and public health practice. According to 
the statement, subjects with hs-CRP levels <1.0 mg/L are at 
low  risk,  those  with  hs-CRP  of  1.0-3.0  mg/L  at  moderate 
risk, and those with hs-CRP  >3.0 mg/L at high risk of of 
vascular  events.  Furthermore,  subjects  with  unexplained, 
sustained  elevation  of  hs-CRP  (>10.0  mg/L)  should  be 
evaluated to exclude non-cardiovascular causes [124-126]. 
  In one study, circulating levels of CRP were found to be 
significantly increased in patients with unstable angina, par-
ticularly  in  those  who  later  develop  an  adverse  vascular 
event. In this study, the relative risk of adverse events asso-
ciated with the highest tertile of CRP levels was 5.2 [127]. In 
another study, CRP levels were associated with an increased 
incidence of major adverse cardiac events  in patients with 
acute myocardial infarction [128]. Also, it was shown that 
CRP levels greater than 10 mg/L independently predict the 
presence of significant coronary lesions [129]. Patients with 
hs-CRP  >3.5  mg/L  had  11-fold  increased  risk  of  cardiac 
events, compared with those with lower levels [130]. 
  Elevated hs-CRP levels are associated with poor quality 
of life, depression, physical inactivity [42], and are predic-
tive of poor outcomes in  coronary atherosclerosis and  left 
ventricular dysfunction [43]. 
  The  role  of  anti-inflammatory  drugs  in  prevention  of 
atherosclerotic events has not been fully elucidated. Some 
studies have demonstrated that anti-inflammatory drugs can 
be useful in prevention of scar formation after catheter pro-
cedures  and  vascular  surgery  [131].  Importantly,  anti-
inflammatory  actions  of  statins  have  been  linked  to  their 
favorable  effects  on  atherosclerosis  [132].  Several  other 
therapeutic  agents  with  anti-inflammatory  properties  are  
being investigated in studies with experimental and clinical 
models of inflammation-associated atherosclerosis. 
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